Stockreport

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Lexeo Therapeutics, Inc.  (LXEO) 
PDF Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious [Read more]